Jeffrey Eisele, Chief Development Officer at Apellis Pharmaceuticals, Inc. (APLS), sold 2,221 shares at $65.53 ($145K) on 2024-01-30, disclosed to the SEC on 2024-01-31.
Scheduled sale ($145k) by Chief Development Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $64.14 | 279 | $18K | 12.3% |
| 2 | $65.53 | 971 | $64K | 43.8% |
| 3 | $65.53 | 971 | $64K | 43.8% |
| Total | $65.36 avg | 2,221 | $145K | 100% |
| Filing → |
| APLS | SELL | 2025-01-14 | $8K | — | Filing → |
| APLS | SELL | 2024-12-27 | $2K | — | Filing → |
| APLS | SELL | 2024-01-24 | $940K | — | Filing → |